SCHEMBL25817287

SCHEMBL25817287

Cc1cc(C2CCN(C(=O)OC(C)(C)C)CC2)c(C2CCOC2)c(C)c1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.45
KDM4E B2RXH2 1/20 0.45
THRB P10828 1/20 0.45
RECQL P46063 1/20 0.43
USP2 O75604 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
GPR119 Q8TDV5 5/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
PTPN2 P17706 1/20 0.40
PTPN1 P18031 1/20 0.40
PTPN6 P29350 1/20 0.40
SCN9A Q15858 1/20 0.39
EPHX2 P34913 1/20 0.38
EED O75530 1/20 0.38
RBBP4 Q09028 1/20 0.38
SUZ12 Q15022 1/20 0.38
EZH2 Q15910 1/20 0.38
AEBP2 Q6ZN18 1/20 0.38
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25817155 0.85 CHRM4 (0.45) MAPTKDM4ETHRBEEDRBBP4
SCHEMBL26780933 0.84 CHRM4 (0.45) MAPTKDM4ETHRBRECQLNPC1
SCHEMBL25817244 0.79 KDM4E (0.52) MAPTKDM4ETHRBGPR119PTPN2
SCHEMBL26780902 0.79 CHRM4 (0.46) MAPTKDM4ETHRBRECQLUSP2
SCHEMBL25817272 0.77 RECQL (0.46) MAPTKDM4ETHRBRECQLUSP2
SCHEMBL23210070 0.76 GPR119 (0.57) MAPTKDM4ETHRBRECQLUSP2
SCHEMBL29691314 0.76 GPR119 (0.57) MAPTKDM4ETHRBRECQLUSP2
SCHEMBL27868117 0.73 GPR119 (0.54) MAPTKDM4ETHRBRECQLUSP2
SCHEMBL25723375 0.73 MAPT (0.50) MAPTKDM4ETHRBRECQLUSP2
SCHEMBL23228680 0.73 SMN1; SMN2 (0.49) MAPTKDM4ETHRBRECQLUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212139-A1 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212139-A1 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS CHRM2, CHRM1, CHRM3 MAPT 3879/4885KDM4E 1919/4885THRB 222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.